These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20493936)

  • 1. Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor.
    Zhu WZ; Wang JX; Shao L; Zhang HX; Zhang QX; Chen JF
    Int J Pharm; 2010 Aug; 395(1-2):260-5. PubMed ID: 20493936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants.
    Zhang JY; Shen ZG; Zhong J; Hu TT; Chen JF; Ma ZQ; Yun J
    Int J Pharm; 2006 Oct; 323(1-2):153-60. PubMed ID: 16828244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability.
    Dhumal RS; Biradar SV; Yamamura S; Paradkar AR; York P
    Eur J Pharm Biopharm; 2008 Sep; 70(1):109-15. PubMed ID: 18502628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability.
    Dhumal RS; Biradar SV; Aher S; Paradkar AR
    J Pharm Pharmacol; 2009 Jun; 61(6):743-51. PubMed ID: 19505364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids.
    Jun SW; Kim MS; Jo GH; Lee S; Woo JS; Park JS; Hwang SJ
    J Pharm Pharmacol; 2005 Dec; 57(12):1529-37. PubMed ID: 16354397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process.
    Park J; Park HJ; Cho W; Cha KH; Kang YS; Hwang SJ
    Int J Pharm; 2010 Aug; 396(1-2):239-45. PubMed ID: 20599602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and characterization of cefuroxime axetil biphasic floating minitablets.
    Jammula S; Patra ChN; Swain S; Panigrahi KC; Nayak S; Dinda SC; Rao ME
    Drug Deliv; 2015 Jan; 22(1):125-35. PubMed ID: 24417642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
    Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
    Freag MS; Elnaggar YS; Abdallah OY
    Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating amorphous mixtures of cefuroxime axetil and copovidone by X-ray diffraction and differential scanning calorimetry.
    Nicolaï B; Perrin MA; Céolin R; Rietveld IB
    Ann Pharm Fr; 2014 Mar; 72(2):95-100. PubMed ID: 24630310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activities of amorphous cefuroxime axetil ultrafine particles prepared by high gravity antisolvent precipitation (HGAP).
    Zhao H; Kang XL; Chen XL; Wang JX; Le Y; Shen ZG; Chen JF
    Pharm Dev Technol; 2009; 14(5):485-91. PubMed ID: 19743947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques.
    Homayouni A; Sadeghi F; Varshosaz J; Afrasiabi Garekani H; Nokhodchi A
    Colloids Surf B Biointerfaces; 2014 Oct; 122():591-600. PubMed ID: 25124835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of bicalutamide nanodispersion for dissolution rate enhancement.
    Li C; Li C; Le Y; Chen JF
    Int J Pharm; 2011 Feb; 404(1-2):257-63. PubMed ID: 21093558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery.
    Kumar BS; Saraswathi R; Kumar KV; Jha SK; Venkates DP; Dhanaraj SA
    Drug Deliv; 2014 May; 21(3):173-84. PubMed ID: 24102185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives.
    Cho E; Cho W; Cha KH; Park J; Kim MS; Kim JS; Park HJ; Hwang SJ
    Int J Pharm; 2010 Aug; 396(1-2):91-8. PubMed ID: 20558265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefuroxime axetil loaded solid lipid nanoparticles for enhanced activity against S. aureus biofilm.
    Singh B; Vuddanda PR; M R V; Kumar V; Saxena PS; Singh S
    Colloids Surf B Biointerfaces; 2014 Sep; 121():92-8. PubMed ID: 24945607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
    Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
    Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process.
    Sui X; Wei W; Yang L; Zu Y; Zhao C; Zhang L; Yang F; Zhang Z
    Int J Pharm; 2012 Feb; 423(2):471-9. PubMed ID: 22183131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronization of atorvastatin calcium by antisolvent precipitation process.
    Zhang HX; Wang JX; Zhang ZB; Le Y; Shen ZG; Chen JF
    Int J Pharm; 2009 Jun; 374(1-2):106-13. PubMed ID: 19446766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of camptothecin (CPT)-loaded folate-conjugated dextran nanoparticles for tumor-targeted drug delivery using supercritical antisolvent method.
    Zhao X; Wang D; Zu Y; Jiang R; Zhao D; Li Y; Zu B; Sun Z; Zhang Q
    J Control Release; 2011 Nov; 152 Suppl 1():e90-2. PubMed ID: 22195950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.